Kejia Ding

554 total citations
25 papers, 444 citations indexed

About

Kejia Ding is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Kejia Ding has authored 25 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Kejia Ding's work include Renal cell carcinoma treatment (6 papers), Renal and related cancers (5 papers) and Cancer Genomics and Diagnostics (4 papers). Kejia Ding is often cited by papers focused on Renal cell carcinoma treatment (6 papers), Renal and related cancers (5 papers) and Cancer Genomics and Diagnostics (4 papers). Kejia Ding collaborates with scholars based in China, Canada and United States. Kejia Ding's co-authors include Hao Ning, Dongbin Bi, Sentai Ding, Jiajü Lü, Shuai Liu, Qiang Fu, Fei Wu, Zhihong Niu, Facheng Wang and Zuohui Zhao and has published in prestigious journals such as Blood, PLoS ONE and Annals of Oncology.

In The Last Decade

Kejia Ding

24 papers receiving 440 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kejia Ding China 15 247 137 131 95 60 25 444
Zongjuan Ming China 13 275 1.1× 130 0.9× 141 1.1× 103 1.1× 30 0.5× 32 480
Kaijing Wang China 13 177 0.7× 134 1.0× 117 0.9× 87 0.9× 61 1.0× 35 417
Kaikai Zhao China 10 222 0.9× 173 1.3× 146 1.1× 108 1.1× 39 0.7× 27 420
Eric Schordan France 12 294 1.2× 86 0.6× 119 0.9× 107 1.1× 31 0.5× 19 482
Jianpeng Yu China 9 281 1.1× 144 1.1× 180 1.4× 84 0.9× 61 1.0× 19 451
Zhongyin Yang China 14 318 1.3× 198 1.4× 174 1.3× 152 1.6× 98 1.6× 39 612
Sundersingh Shirley India 8 246 1.0× 65 0.5× 115 0.9× 116 1.2× 43 0.7× 14 430
Yi‐Fang Yang Taiwan 12 357 1.4× 68 0.5× 224 1.7× 102 1.1× 58 1.0× 29 505
Zhishi Yang China 9 174 0.7× 98 0.7× 212 1.6× 98 1.0× 122 2.0× 10 432
Songming Ding China 12 335 1.4× 72 0.5× 231 1.8× 127 1.3× 62 1.0× 20 510

Countries citing papers authored by Kejia Ding

Since Specialization
Citations

This map shows the geographic impact of Kejia Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kejia Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kejia Ding more than expected).

Fields of papers citing papers by Kejia Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kejia Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kejia Ding. The network helps show where Kejia Ding may publish in the future.

Co-authorship network of co-authors of Kejia Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Kejia Ding. A scholar is included among the top collaborators of Kejia Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kejia Ding. Kejia Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Anagnostou, Valsamo, Paul Wheatley‐Price, Scott A. Laurie, et al.. (2021). FP05.02 A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer. Journal of Thoracic Oncology. 16(10). S952–S952. 2 indexed citations
3.
Jiang, Wei, et al.. (2018). Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer. Oncology Letters. 17(2). 1547–1550. 2 indexed citations
4.
5.
Sun, Liang, Jiajü Lü, Sentai Ding, et al.. (2017). HCRP1 regulates proliferation, invasion, and drug resistance via EGFR signaling in prostate cancer. Biomedicine & Pharmacotherapy. 91. 202–207. 7 indexed citations
6.
Liu, Yi, et al.. (2017). Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis. International Journal of Oncology. 51(2). 435–444. 24 indexed citations
7.
Wang, Zhiyang, Shuai Liu, Kejia Ding, et al.. (2016). Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells. Tumor Biology. 37(11). 15133–15143. 10 indexed citations
8.
Bi, Dongbin, et al.. (2016). miR-1301 promotes prostate cancer proliferation through directly targeting PPP2R2C. Biomedicine & Pharmacotherapy. 81. 25–30. 23 indexed citations
9.
Wu, Fei, Sentai Ding, Xin Li, et al.. (2016). Elevated expression of HIF-lα in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasia. Oncotarget. 7(11). 12053–12062. 14 indexed citations
10.
Sun, Liang, Jiajü Lü, Zhihong Niu, et al.. (2015). A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer. PLoS ONE. 10(12). e0144484–e0144484. 29 indexed citations
11.
Bi, Dongbin, et al.. (2015). Gene expression patterns combined with network analysis identify hub genes associated with bladder cancer. Computational Biology and Chemistry. 56. 71–83. 42 indexed citations
12.
Ye, Changjiang, et al.. (2015). Invasive Epithelioid Angiomyolipoma with Tumor Thrombus in the Inferior Vena Cava: A Case Report and Literature Review. Urologia Internationalis. 98(1). 120–124. 14 indexed citations
13.
Ding, Sentai, Zuohui Zhao, Fei Wu, et al.. (2014). Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma. Tumor Biology. 35(8). 7659–7668. 9 indexed citations
14.
Zhao, Zuohui, Fei Wu, Sentai Ding, et al.. (2014). Label-free quantitative proteomic analysis reveals potential biomarkers and pathways in renal cell carcinoma. Tumor Biology. 36(2). 939–951. 39 indexed citations
15.
Lü, Jiajü, Kejia Ding, Dongbin Bi, et al.. (2013). The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma. Medical Oncology. 30(1). 476–476. 33 indexed citations
16.
Ning, Hao, Qianqian Shao, Kejia Ding, et al.. (2012). Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma.. PubMed. 125(12). 2120–5. 20 indexed citations
17.
Zhang, Xiaoguang, et al.. (2010). PIM‐1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo. Journal of Surgical Oncology. 101(6). 513–519. 14 indexed citations
18.
Ding, Sentai, et al.. (2009). A novel modification of tunical plication by plaque thinning: long-term results in treating penile curvature of Peyronie’s disease. International Urology and Nephrology. 42(3). 597–602. 6 indexed citations
19.
Liu, Zheng, et al.. (2008). Prognostic implication of p27Kip1, Skp2 and Cks1 expression in renal cell carcinoma: a tissue microarray study. Journal of Experimental & Clinical Cancer Research. 27(1). 51–51. 32 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zongjuan Ming Breakdown of academic impact, for papers by Kaijing Wang Breakdown of academic impact, for papers by Kaikai Zhao Breakdown of academic impact, for papers by Eric Schordan Breakdown of academic impact, for papers by Jianpeng Yu Breakdown of academic impact, for papers by Zhongyin Yang Breakdown of academic impact, for papers by Sundersingh Shirley Breakdown of academic impact, for papers by Yi‐Fang Yang Breakdown of academic impact, for papers by Zhishi Yang Breakdown of academic impact, for papers by Songming Ding
Rankless by CCL
2026